The relationship between CSF α-synuclein and established core biomarkers such as Aβ42 and p-tau could advance its diagnostic accuracy and significantly discriminate Alzheimer’s disease with primary α-synucleinopathies. The gene discussed is MAPT; the disease is synucleinopathy.